Report Published: "Iraq Pharmaceuticals & Healthcare Report Q2 2015"

Iraq's attractiveness as a pharmaceutical market is highly dependent on the security situation in the country. With the Islamic State (IS) negatively impacting healthcare access in the north ern states , Iraq's pharmaceutical market appeal to foreign investors has weakened . With IS expected to remain resilient in the nor th in the short term, we highlight Iraq offers a difficult operating environment for drugmakers.

Headline Expenditure Projections

* Pharmaceuticals: IQD2,015bn (USD1.70bn) in 2014 to IQD2,229bn (USD1.80bn) in 2015; +10.6% in local currency and +6.4% in US dollar terms. Forecast upgraded from Q115 due to the availability of new trade data.
* Healthcare: IQD10,346bn (USD8.71bn) in 2014 to IQD11,033bn (USD8.93bn) in 2015; +6.6% in local currency and +2.5% in US dollar terms. Forecast in line with Q115.

Full Report Details at
- http://www.fastmr.com/prod/980246_iraq_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=301

Risk/Reward Index

Iraq's Pharmaceutical Risk/Reward Index (RRI) score for Q215 reflects the market's potential and its strong economic growth prospects. It performs better in terms of Rewards than Risks. In Q215 Iraq scores 39.3 out of 100, making it the 18th most attractive pharmaceutical market in the Middle East and African region out of 31 countries analysed. Its score has slightly decreased and the country lost one position in our index vis-a-vis Q115.

Key Trends And Developments

* The Diyala Health Department, in eastern Iraq, announced it had received approval from the Federal Ministry of Health in March 2015, to open a healthcare centre in Mandali, near the border with Iran.
* In February 2015, Iraq's Ministry of Health announced that it has launched a large scale programme to build cancer research centres across the country.
* It was announced in February 2015 that Iraqi Health Minister, Adila Hammoud, signed a Memorandum of Understanding (MoU) with his Iranian counterpart, confirming that the two countries are keen to cooperate in the field of health, and medical treatment.

BMI Economic View: Growth in the Iraqi economy...

The Iraq Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Iraq Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Iraq pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Iraq, to test other views - a key input for successful budgeting and strategic business planning in the Iraqi pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- United Arab Emirates Pharmaceuticals & Healthcare Report Q2 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q2 2015
- South Korea Pharmaceuticals & Healthcare Report Q2 2015
- Italy Pharmaceuticals & Healthcare Report Q2 2015
- Peru Pharmaceuticals & Healthcare Report Q2 2015